🔍
Search Results - james+barrow
3
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Gut-specific serotonin transporter inhibitors for treatment of constipation
Value Proposition· Potent inhibition of serotonin transporter (SERT) in GI system· Luminally and or/peripherally-restricted SERT inhibitors· Result in enhanced action of serotonin in stimulation of GI motility· Spares the body of systemic and CNS effectsUnmet NeedConstipation-predominant IBS involves reduced gastrointestinal...
Published: 3/13/2025
|
Inventor(s):
Pankaj Pasricha
,
James Barrow
,
Qian Li
,
Pablo de Leon
,
Yifang Huang
Keywords(s):
Antagonists/Inhibitors
,
Biomarker
,
Disease Indication
,
Gastrointestinal Disorders
,
Mechanism-of-action Biomarker
,
Non-novel
,
Predicted Novelty
,
Repurposed
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Technology Classifications > Therapeutic Modalities > Targets
,
Clinical and Disease Specializations > Gastroenterology
Non-acid IP6K Inhibitors
Unmet Need Globally, in 2021, there were approximately 537 million cases of diabetes which resulted in about 6.7 million deaths and $966 billion of healthcare expenditure (IDF). About 95% of diabetes cases are type 2 diabetes (T2D), which is characterized by either impaired insulin production or insulin resistance, and primarily occurs in adults. There...
Published: 3/14/2025
|
Inventor(s):
Tyler Heitmann
,
James Barrow
Keywords(s):
Category(s):
Clinical and Disease Specializations > Diabetes
,
Clinical and Disease Specializations > Diabetes > Type 2 Diabetes
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Therapeutic Modalities > Targets
Design, Synthesis and Structure-activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors
This invention describes a set of novel small molecules that inhibit RNA polymerase I. RNA polymerase I (Pol I) governs the transcription of ribosomal RNAs, which are needed for building and function of the ribosomes. These ribosynthetic activities are greatly increased in cancer cells, and Pol I transcription rate is commonly deregulated in human cancers....
Published: 3/13/2025
|
Inventor(s):
Marikki Laiho
,
Sara Sanders
,
Laureen Colis
,
James Barrow
,
Glen Ernst
Keywords(s):
Antagonists/Inhibitors
,
Cancers
,
Disease Indication
,
Novel
,
Predicted Novelty
,
Small Molecules
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Small Molecules
,
Technology Classifications > Therapeutic Modalities
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum